Skip to main content

Table 5 Slope and intercept from the exposure-response analysis of placebo-corrected QTcN change from baseline by dose

From: The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study

  Slope [ms/(nmol/L)]   Predicted value of placebo-corrected change from baseline QTcN (ms) at gMean of Cmax
Treatment Intercept (ms) Estimate 95% CI gMean of Cmax(nmol/L) Estimate 90% CI
Empagliflozin 25 mg 0.35 -0.0007 -0.0043, 0.0029 768 -0.20 -1.65, 1.24
Empagliflozin 200 mg -0.60 -0.0000 -0.0005, 0.0005 4860 -0.64 -2.33, 1.05
  1. Predicted values and confidence intervals (CI) determined by the exposure-response relationship of empagliflozin (25 mg or 200 mg treatment group). Data from the full analysis set. QTcN, population heart rate-corrected QT interval.